SCHEMBL30342183

SCHEMBL30342183

O=C(NCC(NCCO)C(=O)NC(c1ccc(Cl)cc1)c1ccc(Cl)cc1)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.48
TP53 P04637 1/20 0.46
PSMB1 P20618 1/20 0.44
PSMB5 P28074 1/20 0.44
PSMB2 P49721 1/20 0.44
SLC6A9 P48067 2/20 0.43
CYP3A4 P08684 2/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
PPARA Q07869 2/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
SLC6A5 Q9Y345 1/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CTSS P25774 2/20 0.41
SYK P43405 1/20 0.41
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29005164 0.87 CTSK (0.49) CTSKTP53PSMB1PSMB5PSMB2
SCHEMBL30342202 0.84 SYK (0.53) CTSKTP53PPARACTSSSYK
Benzyl Benzoate SCHEMBL30345166 0.83 KMT2A (0.44) CTSKTP53SLC6A9CYP3A4ALDH1A1
SCHEMBL30345149 0.82 TP53 (0.50) CTSKTP53SLC6A9PPARASLC6A5
Hydrochloric Acid SCHEMBL29005181 0.81 TP53 (0.49) CTSKTP53SLC6A9PPARASLC6A5
SCHEMBL2011885 0.76 SLC6A9 (0.70) TP53SLC6A9CYP3A4ALDH1A1TSHR
SCHEMBL29005203 0.74 CNR1 (0.43) SLC6A9CYP3A4ALDH1A1TSHRSLC6A5
SCHEMBL29005197 0.74 CYP1A2 (0.41) SLC6A9ALDH1A1SLC6A5SMN1; SMN2
SCHEMBL30967604 0.72 SYK (0.58) CTSKPPARACTSSSYKCTSL
SCHEMBL29944675 0.70 TP53 (0.60) CTSKTP53ALDH1A1HTTPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802122-B2 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors MERCK SHARP & DOHME LLC (US) 2023-10-31 US disclosed
US-20230312528-A1 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-10-05 US disclosed
EP-4168393-A1 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS Merck Sharp & Dohme LLC (US) 2023-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802122-B2 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors SCN8A, TRPV1, SCN2A CTSK 914/4885TP53 4874/4885PSMB1 3146/4885
US-20230312528-A1 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS SCN8A, TRPV1, SCN2A CTSK 1068/4885TP53 4877/4885PSMB1 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.